Read the latest research on this blog


 

The basis of evaluation on inflammation should be some of the following markers (“ARB Inflammation Panel”):

  • Plasma levels of circulating intercellular adhesion molecule-1 (cICAM-1)AD.
  • Plasma levels of vascular adhesion molecule-1 (cVCAM-1) A,
  • Serum levels of high-sensitivity C-reactive protein B C E
  • High-sensitivity tumor necrosis factor-alpha B E
  • Interleukin-6 B C
  • Interleukin-10 C
  • Monocyte chemotactic protein-1 B
  • LDL cholesterol serum concentrations B
  • Metalloprotease 9 (MMP-9) C

These were selected because ARB have been demonstrated to impact them and they are recognized as being inflammation markers.

A Angiotensin receptor blockade decreases markers of vascular inflammation. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. J Cardiovasc Pharmacol. 2004 Sep;44(3):335-9.

B Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Circulation. 2004 Aug 31;110(9):1103-7. Epub 2004 Aug 16., 

C Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H. J Am Coll Cardiol. 2004 Jul 21;44(2):362-8.

D Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A.Angiology. 2004 Mar-Apr;55(2):195-203.

E Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. Daneshtalab N, Lewanczuk RZ, Russell A, Jamali F. J Clin Pharmacol. 2004 Mar;44(3):245-52. 

Google

Original 2001 WebSite as PDF for download

Looking for something, look in the Contents or do a Site Search